BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on May 6, Amwell made a grant of RSUs of 3,451 shares of its Class A common stock to one new employee. The grant was offered as material inducement to the employee's employment with Amwell. The RSUs will vest as follows, subject to the employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first calendar day of the month following the

BOSTON, May 01, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL) a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the first quarter ended March 31. Visit Amwell's investor relations website at investors.amwell.com to view the first quarter 2025 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, May 1. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/9tn5fcf6. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. About Amwell Amwell offers payers and

BOSTON, April 24, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based software platform for technology-enabled healthcare, will participate in the following upcoming investor conferences:   On May 8, Mark Hirschhorn, chief financial officer and chief operating officer, will participate in one-on-one meetings at the Needham & Co. Virtual Technology and Services Conference held virtually. On June 24, Hirschhorn will participate in the Truist Securities Healthcare Disruptors & Digital Health Conference in New York City.    About Amwell Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technolo

BOSTON, April 17, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report first quarter 2025 operating results after stock market trading hours on Thursday, May 1 2025. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Amwell offers payers and

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, today announced that, on March 3, 2025, it made a grant of restricted stock units ("RSUs") covering 220,844 shares of its Class A common stock to Dan Zamansky. The grant was offered as material inducement to Zamansky's employment as Amwell's chief product and technology officer. The RSUs become vested as follows, subject to Zamansky's continued employment through each vesting date, except as noted below: 25% of the RSUs will vest on the six-month anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro-rata increments every three (3) m

BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in technology-enabled care, announced Dan Zamansky, an industry leader in innovation and technology, as the company's new chief product and technology officer, effective today. Zamansky will lead the company's product and R&D organizations. He will focus on the comprehensive technology-enabled care platform Amwell offers payers and health systems to provide individuals with better access to more convenient, affordable and effective care. In addition, as more people seek care online and more clinical programs are available, Zamansky will ensure the Amwell platform continues to evolve and provide clients with an integr

BOSTON, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading technology-enabled care platform provider, announced that on Feb. 18, Amwell made grants of RSUs covering an aggregate of 16,737 shares of its Class A common stock to four new employees. The grants were offered as material inducement to the employees' employment with Amwell. The RSUs will vest as follows, subject to the applicable employee's continued employment through the applicable vesting date: 25% of the RSUs will vest upon the first anniversary of the grant date ("Initial Vesting Date"), and the remaining 75% of the RSUs will vest in equal pro rata increments every three months thereafter (beginning on the first

BOSTON, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, will participate in an upcoming investor conference. Ido Schoenberg, M.D., Amwell chairman and chief executive officer, will participate in a fireside chat and one-on-one meetings at the TD Cowen 24th Annual Health Care conference in Boston on March 4. The fireside chat will be at 9:10 a.m. ET and an audio webcast of the fireside chat will be available at investors.amwell.com. About Amwell  Amwell offers payers and health systems a single, comprehensive, technology-enabled care platform. We use technology to provide patients with better ac

BOSTON, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leading provider of a comprehensive SaaS-based technology-enabled healthcare platform, today announced financial results for the fourth quarter and full year ended Dec. 31, 2024. Visit Amwell's investor relations website at investors.amwell.com to view the fourth quarter and full year 2024 earnings report. The company will host a conference call to discuss its financial results today at 5 p.m. ET, Feb. 12. The call can be accessed via a live audio webcast at https://edge.media-server.com/mmc/p/zsp4abpw. A replay of the call will be available via webcast shortly after the completion of the call, at investors.amwell.com. Abo

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, will report fourth quarter 2024 operating results after stock market trading hours on Wednesday, Feb. 12. Following the distribution of the earnings alert via wire services, the Amwell management team will host a live conference call and webcast at 5 p.m. ET to review the company's operating results and provide a general business update. The full earnings report and the live audio webcast can be accessed by visiting the Investors section of the company's website. A webcast replay of the call will be available at investors.amwell.com for approximately 90 days. About Amwell  Am

BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in digital care, today announced Mark Hirschhorn will become Amwell Chief Financial Officer (CFO) effective Oct. 21, succeeding Robert "Bob" Shepardson, who has been in the role since 2021. Hirschhorn will oversee Amwell's financial operations, enterprisewide optimization and capital allocation activities, and will play a meaningful leadership role in guiding the company's strategy to support its long-term growth objectives and enhance shareholder value.   Hirschhorn is a healthcare technology industry leader, with over three decades of experience in financial and strategic operations, having served in senior executiv

Boston, June 17, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE:AMWL), a leader in hybrid care enablement, today announces the appointment of Ricky Goldwasser to the company's Board of Directors, effective June 13. "Ricky brings to our board a deep financial background that makes her an invaluable addition as we focus on Amwell's path to profitability. Ricky's strong voice coupled with her impressive track record will help guide Amwell as we strive for greater efficiencies, optimized cash flow and profitable growth, while remaining committed to enabling our clients to achieve their goals. We are pleased to welcome Ricky to the team," said Ido Schoenberg, M.D., CEO and chairman, Amwell. Ms. Gol

ALACHUA, Fla. and TAMPA, Fla., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, is pleased to announce today the appointment of Mrs. Kathy Weiler to its Board of Directors, effective December 20, 2023. Weiler, a senior executive with 20+ years of experience and proven track record in driving strategic commercial initiatives, will serve on the Board's Governance, Nominating and Sustainability Committee, and the Quality, Compliance, and Portfolio Management Committee. "I am happy to welcome Kathy to the Board as Axogen is approaching an exciting inflection point in its journ

The Amwell Converge™ platform will enable DHA healthcare teams to deliver connected and seamless in-person, virtual, and automated care delivery for the Military Health System Amwell® (NYSE:AMWL), a leader in hybrid healthcare enablement, together with Leidos (NYSE:LDOS), a FORTUNE® 500 science and technology leader, was recently awarded a next-generation contract to provide a hybrid care technology platform designed to power the "Digital First" transformation of the Military Health System (MHS). Under this task order, the Leidos Partnership for Defense Health (LPDH) will deliver Amwell Converge™, a comprehensive hybrid care enablement platform designed to power the full continuum of ca

Industry veteran brings decades of experience driving growth initiatives for top healthcare companies to fuel growth at Amwell Amwell® (NYSE:AMWL), a leader in digital healthcare enablement, today announced the appointment of Kathy Weiler as Executive Vice President, Chief Commercial and Growth Officer, effective June 1, 2023. As a member of Amwell's executive leadership team, Weiler will lead the company's growth strategy, driving strategic initiatives and leading the business development, sales and account management, commercial enablement, marketing, and strategic and channel partnerships teams. Weiler will partner with Amwell clients to help them achieve greater clinical, operational

Amwell®, (NYSE:AMWL) a leader in digital healthcare enablement, today announced the appointment of Robert Webb to the Company's Board of Directors, effective immediately. Mr. Webb will further strengthen the Amwell Board and market position, bringing deep healthcare technology leadership experience, stemming from his more than 30 years as a growth executive, operator, and investor. "As healthcare organizations prioritize digital care to improve patient, member and provider experiences, address workforce shortages, streamline workflows and improve clinical and financial outcomes, Amwell's role as a digital transformation partner has never been more apparent," said Dr. Ido Schoenberg, Chairm

Innovative physician leader brings more than two decades experience to Amwell clinical, go to market and customer success initiatives Amwell® (NYSE:AMWL), a digital care delivery leader, has named Dr. Carrie Nelson as its new Chief Medical Officer. In this role, Dr. Nelson will focus on empowering provider and payer organizations as they seek to achieve greater clinical, operational, and financial outcomes through digital care delivery powered by Converge™, Amwell's enterprise-grade infrastructure software platform. Dr. Nelson will also be responsible for leading clients in their improvement of population health in today's new era of hybrid healthcare and will have clinical oversight of he

Mr. Shepardson will join Amwell on October 31st and will succeed current CFO Keith Anderson following a transition period Amwell®, (NYSE:AMWL) a national telehealth leader, today announced the appointment of Robert Shepardson to the position of Chief Financial Officer (CFO) and Head of Mergers & Acquisitions (M&A). Mr. Shepardson will join the company as CFO on October 31st and will work together during a transition period through the end of 2021 with current CFO Keith W. Anderson. With over 30 years of investment banking and capital markets experience across multiple high-growth sectors, Shepardson brings unmatched expertise in structuring strategic partnerships, restructurings, and debt

Healthcare Industry Veteran O'Grady to Head Growth Organization Amwell®, (NYSE:AMWL) a national telehealth leader, today announced the appointment of Brendan O'Grady to the position of Chief Commercial & Growth Officer, effective immediately. Mr. O'Grady will report to Amwell's Chairman and Co-CEO Ido Schoenberg. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210722005157/en/Brendan O'Grady (Photo: Business Wire) "Brendan has been a meaningful contributor to Amwell's strategy and growth since joining our Board in 2015," said Ido Schoenberg, Chairman and Co-CEO. "His long and impressive track record successfully leading large sca

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

3 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

4 - American Well Corp (0001393584) (Issuer)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G - American Well Corp (0001393584) (Subject)

SC 13G - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

SC 13G/A - American Well Corp (0001393584) (Subject)

Wells Fargo upgraded Amwell from Equal Weight to Overweight and set a new price target of $15.00

Morgan Stanley downgraded Amwell from Overweight to Equal-Weight and set a new price target of $2.50 from $5.00 previously

TD Cowen downgraded Amwell from Outperform to Market Perform and set a new price target of $2.50 from $5.00 previously

Piper Sandler downgraded Amwell from Overweight to Neutral and set a new price target of $3.50 from $5.00 previously

BofA Securities upgraded Amwell from Neutral to Buy and set a new price target of $4.20

Truist initiated coverage of Amwell with a rating of Hold and set a new price target of $5.00

Guggenheim initiated coverage of Amwell with a rating of Buy and set a new price target of $6.00

Credit Suisse resumed coverage of Amwell with a rating of Neutral and set a new price target of $5.00

Wells Fargo reiterated coverage of American Well with a rating of Equal-Weight and set a new price target of $4.00 from $6.00 previously

Goldman initiated coverage of Amwell with a rating of Neutral and set a new price target of $6.00

10-Q - American Well Corp (0001393584) (Filer)

8-K - American Well Corp (0001393584) (Filer)

DEFA14A - American Well Corp (0001393584) (Filer)

DEF 14A - American Well Corp (0001393584) (Filer)

144 - American Well Corp (0001393584) (Subject)

8-K - American Well Corp (0001393584) (Filer)

S-8 - American Well Corp (0001393584) (Filer)

10-K - American Well Corp (0001393584) (Filer)

8-K - American Well Corp (0001393584) (Filer)

8-K - American Well Corp (0001393584) (Filer)